期刊文献+

MACC1、c-Met蛋白在宫颈癌中的表达及与盆腔淋巴结转移的关系研究 被引量:24

Expression of MACC1 and c-Met Proteins in Cervical Carcinoma and its Correlation with Pelvic Lymph Node Metastasis
下载PDF
导出
摘要 目的:探讨结肠癌转移相关基因1(MACCl)、肝细胞生长因子受体(c-Met)蛋白在宫颈癌中的表达及与盆腔淋巴结转移的关系。方法:采用免疫组织化学检测10例正常宫颈组织、17例中~重度宫颈上皮内瘤变组织(CINⅡ~Ⅲ)和91例宫颈癌组织中MACCl、c.Met蛋白的表达情况,分析两者在宫颈癌组织中表达的相关性及与宫颈癌盆腔淋巴结转移的关系。结果:MACCl、c.Met蛋白在宫颈癌组织、CINⅡ~Ⅲ组织中的阳性表达率分别依次为83.5%、76.5%,80.2%、70.6%,均显著高于正常宫颈组织(P〈0.05)。宫颈癌中MACCl蛋白的表达与c.Met蛋白的表达呈正相关(r=0.672,P〈0.05)。将宫颈癌盆腔淋巴结转移组与无转移组进行单因素比较分析,MACCl蛋白表达、c.Met蛋白表达、组织学分化程度、脉管浸润、肌层浸润深度与宫颈癌盆腔淋巴结转移有关(P〈0.05),进一步Logistic回归分析表明,MACCl蛋白表达、肌层浸润深度是宫颈癌盆腔淋巴结转移的独立危险因素(P〈0.05)。结论:MACC1、c.Met蛋白异常表达可能协同参与宫颈癌的恶性进展,MACCl蛋白高表达是宫颈癌盆腔淋巴结转移的独立危险因素。 Objective: To investigate the expressions of metastasis-associated in colon cancer-1 ( MACC1 ), and hepatocyte growth factor receptor (c-Met) in cervical carcinoma and their significance. Methods:The expressions of MACC1 and c-Met in 10 specimens of normal cervical tissue, 17 specimens of moderate-Se- vere cervical intraepithelial neoplasia and 91 specimens of cervical carcinoma were measured by immunohis- tochemistry. The correlations between MACC1 and c-Met protein in cervical carcinoma were analyzed, and the correlations of the 2 proteins with pelvic lymph node metastasis were also evaluated. Results :The posi- tive expression rates in cervical carcinoma and CIN Ⅱ~Ⅲwere 83.5% and 76.5% for MACC1 ; and 80.2% and 70.6% for c-Met; respectively, which were significantly higher than those in normal cervical tissue( P 〈 0. 05). MACC1 expression was positively correlated to c-Met expression( r =0. 672, P 〈 0.05). The single factor comparative analysis between metastasis group and none-metastasis group showed that the expres- sion of MACC1 and c-Met, histological differentiation, vascular invasion, and muscle invasion depth were as- sociated with cervical carcinoma pelvic lymph node metastasis ( P 〈 0. 05 ). Logistic regression analysis showed that MACC1 expression and muscle invasion depth were independent risk factors of cervical carcino- ma pelvic lymph node metastasis (P 〈0.05). Conclusions:Deregulation of MACC1 and c--Met may syner- gistically participate in the malignant progression of cervical carcinoma. The expression of MACC1 is an inde- pendent risk factor of cervical carcinoma pelvic lymph node metastasis.
作者 周娜 吴宜林
出处 《实用妇产科杂志》 CAS CSCD 北大核心 2014年第3期199-203,共5页 Journal of Practical Obstetrics and Gynecology
基金 湖南省科技厅资助项目(编号:2012FJ4068)
关键词 宫颈癌 结肠癌转移相关基因1 肝细胞生长因子受体 盆腔淋巴结转移 Cervical carcinoma Metastasis-associated in colon cancer-1 Hepatocyte growth factor re-ceptor Pelvic lymph node metastasis
  • 相关文献

参考文献10

  • 1Stein U,Walther W,Arlt F. MACC1,a newly identified key regulator of HGF-MET signaling,predicts colon cancer metastasis[J].Nature Medicine,2008,(01):59-67.
  • 2Leo C,Horn L C,Einenkel J. Tumor hypoxia and expression of c-met in cervical cancer[J].Gynecologic Oncology,2007,(01):181-185.
  • 3Stein U,Dahlmann M,Walther W. MACC1-more than metastasis?Facts and predictions about a novel gene[J].Journal of Molecular Medicine,2010,(01):11-18.
  • 4Stein U,Smith J,Walther W. MACC1 controls Met:what a difference an Sp1 site makes[J].CELL CYCLE,2009,(15):2467-2469.
  • 5Arlt F,Stein U. Colon cancer metastasis:MACC1 and Met as metastatic pacemakers[J].International Journal of Biochemistry & Cell Biology,2009,(12):2356-2359.
  • 6Qiu J,Huang P,Liu Q. Identification of MACC1 as a novel prognostic marker in hepatocellular carcinoma[J].Journal of Traditional Medicines,2011,(02):166.
  • 7Huang Y,Zhang H,Cai J. Overexpression of MACC1 and Its significance in human breast cancer progression[J].Cell & Bioscience,2013,(01):16.
  • 8Meng F,Li H,Shi H. MACC1 down-regulation inhibits proliferation and tumourigenicity of nasopharyngeal carcinoma cells through akt/beta-catenin signaling pathway[J].PLoS One,2013,(04):e60821.
  • 9胡兴胜,付曦,文世民,邹心怡,刘雨松.MACC1和c-met在非小细胞肺癌中的表达及其预后价值[J].中国肺癌杂志,2012,15(7):399-403. 被引量:25
  • 10邓欢,李政,李文超,梁卫江.314例Ⅰb~Ⅱa期宫颈癌预后及淋巴结转移危险因素研究[J].中国肿瘤临床,2012,29(10):711-714. 被引量:36

二级参考文献23

  • 1Ho CM, Chien TY, Huang SH, et al. Multivariate analysis of the prognostic factors and outcomes in early cervical cancer patients un- dergoing radical hysterectomy[J]. Gynecol Oncol, 2004, 93(2): 458-464.
  • 2Aoki Y, Sasaki M, Watanabe M, et al. High-risk group in node-positive patients with stage IB, IIA, and IIB cervical carcinoma after radical hysterectomy and postoperative pelvic irradiation[J]. Gynecol Oncol, 2000, 77(2): 305-309.
  • 3Sakuragi N, Satoh C, Takeda N, et al. Incidence and distribution pattern of pelvic and paraaortic lymph node metastasis in patients with Stages IB, HA, and lib cervical carcinoma treated with radical hysterectomy[J]. Cancer, 1999, 85(7): 1547-1554.
  • 4Peters WR, Liu PY, Barrett RN, et al. Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix[J].J Clin Oncol, 2000, 18(8): 1606-1613.
  • 5Monk BJ, Wang j, Im s, et al. Rethinking the use of radiation and chemotherapy after radical hysterectomy: a clinical-pathologic analysis of a Gynecologic Oncology Group/Southwest Oncology Group/Ra- diation Therapy Oncology Group trial[J].Gynecol Oncol, 2005, 96(3): 721-728.
  • 6Chemofsky MR, Felix JG, Muderspach LI, et al. Influence of quantity of lymph vascular space invasion on time to recurrence in women with early-stage squamous cancer of the cervix[J]. Gynecol Oncol, 2006, 100(2): 288-293.
  • 7Marchiole P, Buenerd A, Benchaib M, et al. Clinical significance of lympho vascular space involvement and lymph node micrometastases in early-stage cervical cancer: a retrospective case--control surgico-pathological study[J]. Gynecol Oncol, 2005, 97(3): 727-732.
  • 8Keys HM, Bundy BN, Stehman FB, et al. Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hys- terectomy for bulky stage IB cervical carcinoma[J].N Engl J Med,1999, 340(15):1154-1161.
  • 9Morris M, Eifel PJ, Lu J, et al. Pelvic radiation with concurrent che- motherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer[J].N Engl J Med, 1999, 340(15): 1137-1143.
  • 10Gaarenstroom KN, BonfrerJM, Kenter GG, et al. Clinical value of pretreatment serum Cyfra 21-1, tissue polypeptide antigen, and squamous cell carcinoma antigen levels in patients with cervical cancer[J]. Cancer, 1995, 76(5): 807-813.

共引文献59

同被引文献194

引证文献24

二级引证文献127

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部